Radiopharm Theranostics Limited
Radiopharm Theranostics Limited
Your view on RAD.AX
Overview
What the company does, where it operates, and who runs it.
About Radiopharm Theranostics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Riccardo Canevari
- Headquarters
- 62 Lygon Street, Carlton, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Riccardo Canevari
- Headquarters
- 62 Lygon Street, Carlton, VIC, AU
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic.
The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Radiopharm Theranostics Limited. Starting points for Radiopharm Theranostics Limited: EPS -AUD 0.02, beta 0.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Radiopharm Theranostics Limited. Radiopharm Theranostics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Radiopharm Theranostics Limited. Trailing twelve-month EPS for Radiopharm Theranostics Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterSep 2025 | Next quarterDec 2025 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | −AUD 0.01 | −AUD 0.01 | −AUD 0.01 | −AUD 0.01 |
| Lowest estimate | −AUD 0.01 | −AUD 0.01 | −AUD 0.02 | −AUD 0.02 |
| Highest estimate | −AUD 0.01 | −AUD 0.01 | −AUD 0.00 | −AUD 0.00 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | — | — | −AUD 0.02 | — |
| Growth vs a year ago | — | — | +35.9% | — |
Revenue estimates
| Total | This quarterSep 2025 | Next quarterDec 2025 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 12.14M | AUD 1.00M | AUD 2.33M | AUD 2.64M |
| Lowest estimate | AUD 12.14M | AUD 1.00M | AUD 1.16M | AUD 205333.00 |
| Highest estimate | AUD 12.14M | AUD 1.00M | AUD 3.57M | AUD 5.29M |
| Number of analysts | 1 | 1 | 5 | 3 |
| A year ago | — | — | AUD 2.77M | — |
| Growth vs a year ago | — | — | −15.7% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Radiopharm Theranostics Limited. Radiopharm Theranostics Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ADO.AXAnteoTech Limited | Basic Materials | Chemicals - Specialty | — | ||
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| ATX.AXAmplia Therapeutics Limited | Healthcare | Biotechnology | — | ||
| CSX.AXCleanSpace Holdings Limited | Healthcare | Medical - Devices | — | ||
| CTE.AXCryosite Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| CYP.AXCynata Therapeutics Limited | Healthcare | Biotechnology | — | ||
| DOC.AXDoctor Care Anywhere Group PLC | Healthcare | Medical - Healthcare Information Services | — | ||
| NSB.AXNeuroScientific Biopharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PREDQPredictive Discovery Limited | Healthcare | OTC | $2,996 | ||
| PREV.CNPreveCeutical Medical Inc. | Healthcare | CNQ | $11.7M | ||
| PRLDPrelude Therapeutics Incorporated | Healthcare | NASDAQ | $191.0M | ||
| PRMEPrime Medicine, Inc. | Healthcare | NASDAQ | $694.9M | ||
| PRNAFAlterity Therapeutics Limited | Healthcare | OTC | $109.8M | ||
| PROKProKidney Corp. | Healthcare | NASDAQ | $349.7M | ||
| PROTProteonomix, Inc. | Healthcare | OTC | $791 | ||
| PRQRProQR Therapeutics N.V. | Healthcare | NASDAQ | $155.2M | ||
| PRRUFImmutep Limited | Healthcare | OTC | $368.0M | ||
| PRTAProthena Corporation plc | Healthcare | NASDAQ | $428.8M | ||
| PRTCYPureTech Health plc | Healthcare | OTC | — | ||
| PRVCFPreveCeutical Medical Inc. | Healthcare | OTC | $10.1M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Radiopharm Theranostics Limited. Coverage tracks Radiopharm Theranostics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Radiopharm Theranostics Limited.